Guangdong Jiaying Pharmaceutical Co Ltd

Guangdong Jiaying Pharmaceutical Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to CNY 49,482,400, which significantly exceeds its total liabilities of CNY 62,021,880. The company's operating cash flow of CNY 13,858,810 supports its liquidity, although its capital expenditure of CNY -29,452,790 indicates a significant outflow for investment in infrastructure or equipment. In terms of profitability, the company's revenue of CNY 150,038,530 reflects its market position in the pharmaceutical industry. However, without access to industry-specific metrics such as EBITDA margins or ROIC, a direct comparison to industry medians is not possible at this time. The company's geographic exposure is primarily concentrated in China, as disclosed in its business operations. There is no available data on segment-specific revenue contributions, which limits the ability to assess diversification across product lines or geographic regions. The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of outlook data makes it difficult to assess the company's future performance. The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure appears stable, with no dilution potential identified in the basic shares outstanding. There are no recent events or filings disclosed in the available data that would impact the company's operations or financial position. The absence of recent transcripts or filings suggests a lack of public commentary or regulatory actions affecting the company.